Definium Therapeutics, Inc.

NASDAQ:DFTX

Biotechnology

Healthcare
$29.12 -1.67%

-$0.41 today

Market cap
$3.99B
Beta
2.38
P/E (TTM)
-11.0
EPS (TTM)
-$2.18
52W Low $12.88High $26.15

Volume 1.91M

Average 2.67M

DFTX EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Definium Therapeutics, Inc.NASDAQ: DFTX

EBITDA · Q3 FY2026 · quarter ended Sep 2026

EBITDA remains negative

Q3 FY2026 EBITDA was -$49.81M, compared with -$65.98M a year earlier. Trailing-twelve-month EBITDA was -$323.53M.

Context

  • EBITDA grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -68.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$49.81M+68.4% QoQ
Last fiscal yearDec 2025
-$178.31M-68.4% YoY
LTMSep 2026
-$323.53M-99.1% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+24.5%+100.0%+75.5 pp
1 year-68.4%+100.0%+168.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(178.31M) USD
Year-over-year change
-68.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How DFTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -99.1% is the 8th highest of 10, against a peer median of -28.2%.
DFTX Competitors
EBITDA for DFTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ATHEAlterity Therapeutics LimitedFY2025-A$14.63M AUD+25.2%—269.0%
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026-$39.05M USD———
GHRSGH Research PLCLTM Mar 2026-$55.86M USD-33.8%——
ANROAlto Neuroscience, Inc.LTM Mar 2026-$71.29M USD-16.9%——
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026-$118.15M USD-28.2%—590.7%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026-$176.13M USD+22.9%—22.7%
MPLTMapLight Therapeutics, Inc.LTM Mar 2026-$198.91M USD-147.8%——
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026-$217.64M USD+15.4%——
DFTXDefinium Therapeutics, Inc.LTM Sep 2026-$323.53M USD-99.1%——
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026-$359.29M USD-31.7%——
NERVMinerva Neurosciences, Inc.LTM Jun 2026-$394.35M USD-3608.6%——
Peer median (excluding DFTX) —-28.2%—269.0%

Competitors are the stored peer set for DFTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue003.16M527K0
Gross Profit00(3.16M)(527K)0
Gross Margin—————
Research & Development34.79M36.17M48.96M65.3M117.67M
Selling, General & Admin59.07M30.16M41.74M38.62M48.64M
Operating Expenses93.85M66.33M90.7M103.39M166.31M
Depreciation & Amortization2.62M3.18M3.16M527K0
EBITDA(91.22M)(52.12M)(92.57M)(105.87M)(178.31M)
EBITDA Margin—————
Operating Income(93.85M)(66.33M)(93.87M)(103.92M)(166.31M)
Operating Margin—————
Interest Income01.5M5.58M11.56M10.96M
Interest Expense359K1.5M920K2.28M5.48M
Other Income / Expenses(339K)9.54M(1.87M)(4.76M)(17.48M)
Income Before Tax(94.19M)(56.8M)(95.73M)(108.68M)(183.79M)
Pre-Tax Margin—————
Income Tax Expense(1.16M)0000
Net Income(93.04M)(56.8M)(95.73M)(108.68M)(183.79M)
Net Margin—————
EPS (Basic)(3.40)(1.53)(2.44)(1.54)(2.06)
EPS (Diluted)(3.40)(1.53)(2.44)(0.15)(2.06)
Weighted Avg Shares27.38M30.86M39.16M70.46M89.33M
Weighted Avg Shares (Diluted)27.38M30.86M39.16M704.61M89.33M

Definium Therapeutics, Inc.

NASDAQ:DFTX

Intrinsic Alpha fair value

Locked

Current Price

$29.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.